Zomanex Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Zomanex General Information

Description

Operator of a drug formulation development company intended to transform injectable and oral therapeutics into novel orally delivered medicines. The company's products help in the conversion of injectable xenobiotics into orally deliverable substances, as well as make it easy for hydrophobic compounds to be absorbed in the small intestine, enabling physicians to permit oral dosing of pharmaceutical compounds that have previously been administered intravenously or by injection.

Contact Information

Website
www.zomanex.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Suite 2600 Three Bentall Centre
  • Post Office Box 49314, 595 Burrard Street
  • Vancouver, British Columbia V7X 1L3
  • Canada
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Suite 2600 Three Bentall Centre
  • Post Office Box 49314, 595 Burrard Street
  • Vancouver, British Columbia V7X 1L3
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zomanex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 11-Feb-2025 Completed Out of Business
1. Later Stage VC (Series A) 12-Oct-2017 Completed Generating Revenue
To view Zomanex’s complete valuation and funding history, request access »

Zomanex Patents

Zomanex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2008309010-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007
AU-2008309010-B2 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Inactive 28-Sep-2007
CA-2701023-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007
CA-2701023-C Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Inactive 28-Sep-2007
EP-2205219-A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms Active 28-Sep-2007 A61K31/337
To view Zomanex’s complete patent history, request access »

Zomanex FAQs

  • When was Zomanex founded?

    Zomanex was founded in 2006.

  • Where is Zomanex headquartered?

    Zomanex is headquartered in Vancouver, Canada.

  • What industry is Zomanex in?

    Zomanex’s primary industry is Drug Discovery.

  • Is Zomanex a private or public company?

    Zomanex is a Private company.

  • What is Zomanex’s current revenue?

    The current revenue for Zomanex is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process